Based on the huge population base, as well as the aging of aging, consumption and other factors, the global oncology drug market is growing, according to data, it has increased from 83.
2 billion US dollars in 2015 to 165.
3 billion US dollars in 2020, with an average annual growth rate of 14.
7%.
Following this trend, the global oncology drug market is expected to grow
at an average annual rate of 10% between 2021 and 2026.
It is worth noting that with the continuous expansion of the oncology drug market, a large number of pharmaceutical companies at home and abroad have begun to focus on the field of
oncology.
For example, more than 1,000 clinical trials of 19 multinational pharmaceutical companies such as AbbVie, Amgen and AstraZeneca compiled by Guosheng Securities show that tumors have accounted for nearly half
of the total R&D pipeline.
In this context, pharmaceutical companies are intensifying their "involvement" in new tumor drugs, and at the same time, pharmaceutical companies have begun to usher in more and more new breakthroughs
in research and development.
For example, on December 2, Henlius announced on the Hong Kong Stock Exchange that the company's self-developed HLX60 (recombinant anti-GARP humanized monoclonal antibody injection) for the treatment of solid tumors and lymphomas completed the dosing
of the first patient in China (excluding Hong Kong, Macao and Taiwan).
HLX60 is an innovative anti-GARP monoclonal antibody independently developed by the company, which is planned to be used in the treatment
of solid tumors and lymphomas.
On December 1, Roche published new data from the Phase III IMscin001 study of the subcutaneous formulation of the PD-L1 antibody atezolizumab (Tecentriq): In previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), subcutaneous atezolizumab has comparable exposure (molecular level in the blood) and similar efficacy and safety
compared with standard intravenous infusion.
Currently, Roche has submitted data from the IMscin001 study to regulatory agencies worldwide and sought approval for all approved indications for intravenous infusion dosage forms for atezolizumab subcutaneous formulations
.
If approved, atezolizumab would be Roche's fourth subcutaneous antitumor therapy
.
On November 24, Huahai Pharmaceutical announced that its subsidiary Shanghai Huaaotai's independent research and development of HB0045 injection for the treatment of advanced solid tumors was approved
by the US Food and Drug Administration (FDA).
It is understood that HB0045 is the first compound preparation targeting human CD73 (also known as extracellular-5'-nucleotidase) at home and abroad, which can completely inhibit the activity of membrane and soluble CD73 enzyme through the dual mechanism of allostericization and steric hindrance without affecting the binding of AMP (adenosine monophosphate) substrates, thereby reducing the production of adenosine in the tumor microenvironment (TME), promoting the activation of immune cells in the tumor microenvironment and inhibiting tumor growth
.
Prior to this, Ascentage Pharma also announced that the company's application for a new drug clinical trial (IND) for the treatment of anemia-related diseases by APG-5918, an innovative embryonic ectoderm development protein (EED) inhibitor, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, which will open the exploration
of non-oncology fields.
APG-5918 is the first Chinese original EED inhibitor to enter the clinical stage, and is advancing clinical research
in China and the United States for the treatment of advanced solid tumors or hematologic malignancies.
In general, anti-tumor drugs are a hot target for domestic and foreign pharmaceutical companies
.
It can be seen from the fact that a large number of domestic anti-tumor new drugs have begun to usher in new progress in research and development, and it can be seen that the innovative research and development of anti-tumor innovative drugs in China is advancing
rapidly.
The industry expects that in the future, attracted by the huge market prospects, the enthusiasm for innovation of domestic pharmaceutical companies will continue to rise, and more domestic anti-tumor new drugs will continue to emerge, benefiting the majority of patients
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
